.
IR (KBr, cm -1 ): 3447, 3028, 2956, 2862, 1741, 1701, 1660, 1592, 1351, 1244, 778 . 164.06, 163.97, 162.44, 145.42, 137.02, 136.94, 131.75, 130.88, 129.98, 129.07, 128.49, 127.06, 125.73, 125.73(J = 3.4 Hz), 123.29, 120.16, 117.67, 117.45, 40.37, 30.30, 20.50, 13.98 .
ESI-HRMS (m/z):
IR (KBr, cm -1 ): 3449, 3030, 2959, 2863, 1688, 1648, 1584, 1495, 1380, 1347, 1227, 778 . 164.17, 164.10, 145.26, 142.63, 136.36, 131.69, 131.56, 131.01, 130.43, 130.08, 129.11, 129.03, 128.60, 127.70, 126.88, 123.91, 123.32, 119.67, 40.34, 30.32, 20.74, 20.51, 13 .99.
ESI-HRMS

S5
IR (KBr, cm -1 ):3449, 3025, 2958, 2862, 2360, 1697, 1652, 1583, 1511, 1461, 1353, 1231, 164.13, 164.11, 144.50, 135.36, 131.57, 130.82, 130.18, 129.67, 129.03,129.03, 128.95, 128.95, 127.99, 126.79, 124.06, 123.22, 119.73, 40.35, 37.52, 30.32, 20.52, 14 .00.
IR (KBr, cm -1 ): 3450, 3027, 2959, 2863, 2361, 1695, 1647, 1589, 1504, 1457, 1357, 1232, 1074, 778 . 163.64, 163.44, 162.55, 147.86, 135.07, 131.55, 130.74, 128.47, 128.24, 128.18, 128.18, 128.02, 127.38, 124.99, 123.55, 123.55, 115.25, 115.25, S6 55.63, 40.51, 30.20, 20.43, 13.92 .
ESI-HRMS
IR (KBr, cm -1 ):3447, 3033, 2960, 2865, 2363, 1741, 1704, 1586, 1499, 1356, 1300, 1260, 1082, 758 . 163.83, 163.53, 155.76, 149.00, 133.13, 132.19, 131.72, 130.80, 129.59, 128.41, 128.31, 127.67, 125.82, 125.16, 124.94, 123.30, 122.16, 111.34, 55.69, 40.53, 30.27, 20.47, 13.93 .
ESI-HRMS (m/z):
IR (KBr, cm -1 ): 3448, 3024, 2925, 2865, 2360, 1694, 1654, 1583, 1475, 1353, 1271, 1233, 1040, 780 . (m, 2H), 7.79 (t, J = 7.9 Hz, 1H), 7.70-7-67 (m, 2H), 7.10 (t, J = 8.2 Hz, 2H), 4.15 (t, J = 7.5 Hz, 2H), 1.73 -1.62 (m, 2H), 1.47 -1.36 (m, 2H), 0.95 (t, J = 7.3 Hz, 3H).
13 C NMR (100 MHz, CDCl 3 , δ): 163.53, 163.30, 147.58, 139.91, 139.88, 131.73, 130.72, 128.60, 128.28, 128.06, 128.06, 127.97, 127.58, 125.43, 123.92, 123.76, 117.31, 117.09, 40.57, 30.23, 20.44, 13 .90.
S7
IR (KBr, cm -1 ): 3498, 3027, 2925, 2864, 2361, 1700, 1663, 1583, 1493, 1340, 1299, 1061, 781 . 197.94, 169.85, 162.99, 151.44, 150.37, 136.31, 135.00, 134.67, 132.37, 131.43, 130.80, 130.05, 128.36, 126.40, 124.91, 124.25, 122.43, 122.33, 118.97, 26.80, 21.15 .
ESI-HRMS (m/z):
S8
IR (KBr, cm -1 ): 3448, 3028, 2957, 2862, 2361, 1704, 1656, 1583, 1512, 1352, 1227, 1044, 781 . 163.64, 163.49, 146.23, 131.54, 130.42, 130.33, 130.33, 128.78, 128.63, 128.63, 128.34, 127.99, 127.92, 127.87, 127.43, 124.95, 124.44, 123.54, 62.64, 40.62, 30.27, 20.49, 13.94 . 163.65, 163.22, 157.30, 141.73, 136.43, 131.58, 131.18, 130.49, 129.91, 129.24, 128.79, 128.67, 128.32, 127.30, 127.13, 123.28, 121.01, 112.73, 55.89, 40.63, 30.21, 20.45, 13 .94.
ESI-HRMS (m/z):
IR (KBr
S9
IR (KBr, cm -1 ): 3449, 3024, 2962, 2926, 2361, 1740, 1705, 1623, 1476, 1374, 1343, 1284, 1147, 790 . 162.87, 141.39, 136.71, 136.68, 131.97, 130.77, 130.68, 130.28, 129.77, 129.69, 129.21, 129.11, 127.73, 127.12, 123.53, 117.19, 116.96, 40.67, 30.17, 20.43, 13.92 . 163.49, 162.98, 141.32, 138.50, 138.34, 134.40, 133.22, 131.88, 130.45, 129.92, 129.47, 129.29, 129.03, 128.93, 127.47, 127.13, 126.97, 123.41, 40.66, 30.19, 20.44, 20.31, 13. 
ESI-HRMS (m/z):
IR (KBr
Fluorometric analysis method
Deionized water was used to prepare all aqueous solutions. All the photophysical characterization experiments were carried out at 37 o C. Phosphate buffer saline (PBS, 10 mM, pH 7.4) was purged with nitrogen for 5 min before use. Na-8 was dissolved in DMSO to make a 5 mM stock solution. GSH and other reactive bio-relevant species were prepared by dissolving commercial reagents in H 2 O. To test the fluorescent responses of Na-8 towards GSH or other reactive species, aliquots of probe stock solution were diluted with PBS (with 1‰ cetrimonium bromide) and treated with analytes to make sure both probes and analytes were kept at desired final concentrations. After quick and vigorous shaking, the mixture was allowed standing in the dark at 37 o C for desired time and the fluorescent spectra were then recorded under excitation at 405 nm. The emission spectra were scanned from 410 to 650 nm.
All fluorometric experiments were performed in triplicate, and data shown were the average.
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Fig. S1
Fluorescent spectra of Na-8 (5 μM) after the treatment of GSH (100 μM) for various time. 
S14
Step 1: Blank measurements (n=25). Mean: F B = 0.15136 ± 0.06212;
Step 2: Linear regression analysis on fluorescence intensity and the corresponding GSH concentrations (0-10 μM):
Step 3 
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Fig. S9
The liquid chromatogram (LC) traces of Na-8 before or after the treatment of various concentrations of GSH for 20 min. The peak corresponding to Na-8 decreased in a GSH-dose independent way accompanied by the simultaneous increase of a new peak whose structure was elucidated by MS analysis to be the nucleophilic substitution product of Na-8 by GSH. 
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Fig. S12 Na-8 detects GSH irreversibly. A solution of Na-8 (5 μM) was treated with GSH (500 μM) for 60 min, and then aliquots of the solution were further treated with N-methyl maleimide (NMM) of various concentrations for 30 min to record the emission spectra.
Fig. S13
Emission spectra of Na-8 (5 μM) after various treatment. A) Na-8 (5 μM) was treated with GSH (0.5 mM) for 0.5 h. Then an aliquot of the solution was treated with NMM (1.0 mM) to consume the remaining GSH. After another 0.5 h, ONOO -(10 μM) was added to an aliquot of the solution containing little free GSH and the mixture was allowed to incubate for a further 0.5 h. Next, an aliquot of the ONOO --treated solution was incubated with GSH (1.0 mM) for 0.5 h. detects irreversibly. Finally, all the solutions were recorded for their emission spectra. B) GSH (0.5 mM) without or with the pretreatment of NMM (30 min) induced different degree of Na-8 (5 μM). 
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Biological Methods
Cell culture
L02 and HepG2 cells were cultured in RPMI 1640 (Gibco, 31800022) and DMEM (Gibco,12100061) growth medium supplemented with 10% FBS (Gibco, Australia) in a humidified atmosphere of 5% CO 2 and 95% air at 37 C and split when the cells reached 95% confluency.
Fluorescence imaging
Generally, cells (HepG2, 25000/well; L02, 20000/well) were seeded on a black 96-well microplate with optically clear bottom (Greiner bio-one, Germany) overnight. For direct fluorescent quantitation, cells were loaded with probe Na-8 (10 μM) or monochlorobimane (20 μM) for 30 min. For exogenous GSH detection, HepG2 cells were firstly loaded with the probe Na-8 (10 μM) in culture medium for 30 min and changed to fresh one containing GSH (Sigma, G4251) of 1.0 mM and 2.0 mM for another 10 min. For endogenous GSH detection, cells were incubated with NEM (Sigma, E3876) of 25 μM and 50 μM for 30 min, after which the probe Na-8 (10 μM) was added to the medium for further 30 min. After incubation, all the above were washed with PBS twice before image. For NAC treatment, cells were pretreated with NEM (50 μM) for 15 min, then probe Na-8 (10 μM) was added to culture medium for another 15 min. After that cells were changed to the fresh culture medium containing probe Na-8 (10 μM) and NAC (100 μM), and imaged at indicated time. The fluorescence images were recorded by Operetta high content imaging system (Perkinelmer, US) at the excitation wavelengths of 360-440 nm. The fluorescence was quantified by columbus analysis system (Perkinelmer, US).
Cell viability assay
Cell viability was detected by MTS assay as the guidelines. 10 μL per well of MTS/PMS (20:1, Promega Corp) solution was added to each well containing 100 μL of culture medium, followed by a gentle shake. After incubation at 37 °C under 5% CO 2 for 4 h, the absorbance of the solutions was measured at 490 nm, using an M5 microplate reader (Molecular Device, USA).
For drug-resistance assay, cells (L02 10000/well; HepG2 15000/well)were seeded on 96-well microplates in growth medium overnight and exposed to increasing concentration of Cisplatin (0, 0.5, 1, 2.5, 5, 10, 20 μM; Selleck S1166) or Doxorubicin (0, 0.01, 0.025, 0.05, 0.1, 0.25, 0.5 μg/ml; Selleck S1208) for 72 h.
To test if GSH invovled in this process, cells were firstly pretreated with BSO (50 μM; Sigma B2515) for 24 h, followed by exposed to increasing concentration of Doxorubicin (0, 0.05, 0.1, 0.25, 0.5 μg/ml) in absence or in presence of BSO (50 μM) for another 48 h. Or cells were pretreated with Doxorubicin (0.25 μg/ml) for 24 h, followed by exposed to Doxorubicin (0.25 μg/ml) in presence of BSO (0, 12.5, 50 μM) for 48 h. And the Cisplatin (0, 0.5, 1, 2.5, 5, 10, 20 μM; 5 μM) was tested as the same.
For short-term toxicity test, cells (L02 10000/well; HepG2 15000/well)were seeded on 96-well microplates in growth medium overnight and exposed to increasing concentration of probe Na-8 (1, 5, 10, 20 μM) for 1 h. Then cells were changed to the fresh culture medium for S20 were seeded on 96-well microplates in growth medium overnight and exposed to increasing concentration of probe Na-8 (1, 5, 10, 20 μM) for 48 h. Then cells were changed to the fresh culture medium just before MTS assay.
ROS detection
ROS was deteced by the Reactive Oxygen Species Assay Kit (Yeasen, 50101ES01). Cells (HepG2, 160000/well; L02, 140000/well) were seeded on a 24-well microplate in growth medium overnignt and treated with Doxorubicin (0.25 μg/ml) for the indicated time (0, 15, 30, 60 min). After the medium was removed, the cells were loaded with probes DCFH-DA in the phenol red -free medium for 30 min. After a quick wash, cells were trypsinized and analyzed by flow cytometry. 
Statistical analysis
Unpaired T-test was performed to analyze the results using GraphPad Prism software.
Results (Figure5-8) are presented as mean ± S.D. Results in Figure 9 are presented as mean ± SEM. Statistical significance was determined at P < 0.05(*); P < 0.01(**); P < 0.001(***). 
